Latest Content

See the latest developments in narcolepsy research.

Syremis Therapeutics advances innovative drugs ST-905 and ST-901 for schizophrenia and major depressive disorder, aiming to transform mental health treatment.

During the holidays, can we blend tradition with modern media habits without sacrificing the meaning?

Cobenfy gains NMPA approval in China, offering a groundbreaking treatment for schizophrenia with a unique mechanism and improved symptom management.

In this CME article, explore effective strategies for managing sleep disturbances in elite athletes, focusing on pharmacologic and nonpharmacologic interventions.

Reviva Pharmaceuticals announced FDA recommendations from their pre-NDA meeting on brilaroxazine for schizophrenia.

Discover engaging holiday reads that blend entertainment with profound insights, featuring classics and modern works that explore the human psyche.

An open letter urges lawmakers to regulate AI chatbots, highlighting their dangers to children's emotional development and mental health.

The tragedy sheds light on the complexities of parricide and loss.

Discover how access to nature enhances mental health, promoting healing and resilience through green spaces and innovative therapeutic practices.

Explore the transformative impact of lifestyle psychiatry on mental health, emphasizing exercise, nutrition, and connectedness for improved well-being in our latest Special Report.

Explore the legacies of Milwaukee's influential psychiatrists, Jon Gudeman and Scott Sandage, and their impact on mental health and culture.